Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 146-152

  Berg, Karina ^a,b   Pedersen, Terje R ^a,b   Sandvik, Leiv ^a   Bragadóttir, Ragnheiour ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEUROLOGIC DISEASE; NORWAY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA MACULA HEMORRHAGE; RETINA TEAR; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VEIN THROMBOSIS; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84920748073     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.041     Document Type: Article

References (13)

1. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
2. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36: 336-9.
3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
4. Kodjikian L, Souied EH, Mimoun G, et al; GEFAL Study Group. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120: 2300-9.
5. Krebs I, Schmetterer L, Boltz A, et al; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
6. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382: 1258-67.
7. Spaide RF. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 2009;148:1-3.
8. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33: 1351-8.
9. Brown DM, Michels M, Kaiser PK, et al; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116: 57-65.
10. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
11. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1419-31.
12. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
13. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9